Given this mechanism, the abnormal activation of the Hh signalling pathway and the CCL20–CCR6 axis serve not only as a potential biomarker for HCC but also represent a promising therapeutic target to inhibit tumour growth and improve patient outcomes in HCC. This evidence concerns the gene CCR6 and neoplasm.